Drug Research
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
Editas Medicine, Inc., a leading genome editing company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that they have entered into...
Drug Research
Seven Indian Drugmakers Race To Develop Covid-19 Vaccine
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E among domestic pharma firms working on the vaccines in India
At least seven Indian pharma companies are working to develop a vaccine against coronavirus as they...
Drug Research
BioInvent’s BI-1206 could improve treatment in several cancers
Alexander Eggermont, MD, PhD, Chief Scientific Officer at the Princess Máxima Center and renowned expert in immunotherapy showcased the broad potential of BI-1206 in enhancing checkpoint inhibitors in solid cancers in a KOL event hosted by BioInvent on July...
Drug Research
Catalent Biologics to Invest $30 Million to Create European Clinical Manufacturing Center of Excellence in France
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it plans to invest $30 million (€27 million) at its facility in Limoges,...
Drug Research
GSK and CureVac announce strategic mRNA technology collaboration
GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA...
Drug Research
CMIC Group Establishes a New Biologic Contract Development and Manufacturing Business in Japan
CMIC HOLDINGS Co., Ltd. announced the establishment of CMIC BIO Co., Ltd. (hereafter CMIC BIO), a fully-owned subsidiary that offers Contract Development and Manufacturing Organization (hereinafter CDMO) services for biopharmaceutical drug substance. CMIC Bio has a single-use facility in...
Drug Research
CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate
CEPI, the Coalition for Epidemic Preparedness Innovations, announced the expansion of its partnership with Sichuan Clover Biopharmaceuticals, Inc to rapidly advance the development and manufacture of Clover’s protein-based COVID-19 S-Trimer vaccine candidate, which is based on Clover’s proprietary Trimer-Tag©...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read